EPISODE · Mar 20, 2026 · 26 MIN
Contextualizing the Data for Novel First-Line HER2+ mBC Maintenance Therapies: How Might the Treatment Paradigm Change?
from CME in Minutes: Education in Oncology & Hematology · host Answers in CME
Please visit answersincme.com/860/100850799-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by William J. Gradishar, MD, FASCO, FACP and Otto Metzger, MD. In this activity, experts in breast cancer discuss the clinical implications of recent data on first-line maintenance strategies in HER2-positive metastatic breast cancer. Upon completion of this activity, participants should be better able to: Summarize the latest evidence supporting novel first-line maintenance strategies in HR-positive, HER2-positive mBC; and Determine evidence-based practical approaches with evolving first-line maintenance treatment to optimize care for patients with HR-positive, HER2-positive mBC.
What this episode covers
Please visit answersincme.com/860/100850799-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by William J. Gradishar, MD, FASCO, FACP and Otto Metzger, MD. In this activity, experts in breast cancer discuss the clinical implications of recent data on first-line maintenance strategies in HER2-positive metastatic breast cancer. Upon completion of this activity, participants should be better able to: Summarize the latest evidence supporting novel first-line maintenance strategies in HR-positive, HER2-positive mBC; and Determine evidence-based practical approaches with evolving first-line maintenance treatment to optimize care for patients with HR-positive, HER2-positive mBC.
NOW PLAYING
Contextualizing the Data for Novel First-Line HER2+ mBC Maintenance Therapies: How Might the Treatment Paradigm Change?
No transcript for this episode yet
Similar Episodes
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m
Nov 12, 2025 ·35m
Oct 17, 2025 ·40m